BIOLASE Technology (ticker: BLTI, exchange: NASDAQ)
BIOLASE Technology Gets FDA Approval for Laser Use in Periodontal Procedures
SAN CLEMENTE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- BIOLASE Technology, Inc. (Nasdaq: BLTI) a medical technology company that develops, manufactures and markets lasers and related products focused on pain-free medical and dental procedures, announced today that it has obtained the first-ever clearance from the US Food and Drug Administration (FDA) for periodontal procedures for both early and advanced stages of periodontal disease for a 810nm solid-state laser system, LaserSmile(TM).
The new clearances for the LaserSmile now include soft tissue curettage; removal of diseased, infected inflamed and necrosed soft tissue within the periodontal pocket; and removal of highly inflamed edematous tissue affected by bacteria penetration of the pocket lining and junctional epithelium. The LaserSmile previously had FDA clearance for cosmetic and soft-tissue applications including tooth whitening, cosmetic gingival contouring, crown lengthening, treatment of herpetic lesions and aphthous ulcers, gingival troughing, sulcular debridement in the periodontal pocket, and other indications.
Jeffrey W. Jones, BIOLASE CEO and President, commented, "With more than 30% of adults over 50 suffering from periodontal disease, this additional new clearance expands the market for BIOLASE products. This new clearance also covers soft tissue curettage for post extraction tooth socket, which represents more than 30 million potential treatments per year, further entrenching BIOLASE's position as the world leader in the dental laser market."
BIOLASE Technology, Inc. ( http://www.biolase.com ) is a medical technology company that designs, manufacturers and markets proprietary dental laser systems that allow dentists, oral surgeons and other specialists to perform a broad range of common dental procedures, including cosmetic applications. The company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase system, is the best selling dental laser system. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The company also offers the LaserSmile system, which uses a laser to perform soft tissue and cosmetic procedures, including tooth whitening. In May 2003, the company acquired the American Dental Laser product line, including the Diolase and Pulsemaster systems, which can be used for common soft tissue procedures.
The matters discussed in this news release include forward-looking statements that are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to, the effect of actions of third parties, including governmental officials, the timely development and acceptance of new products, the impact of competitive products and pricing, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. Actual results may differ materially from those projected. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.
SOURCE BIOLASE Technology, Inc. -0- 10/20/2003 /CONTACT: Jeffrey W. Jones, President & CEO of BIOLASE Technology, Inc., +1-949-361-1200, firstname.lastname@example.org; or Investor Relations, Linda Decker, email@example.com , or Christian Pflaumer, firstname.lastname@example.org , both of Porter, LeVay & Rose, Inc., +1-212-564-4700, for BIOLASE Technology, Inc./ /Web site: http://www.biolase.com / (BLTI) CO: BIOLASE Technology, Inc. ST: California IN: MTC BIO HEA SU: PDT ES-KK -- LAM071 -- 1581 10/20/2003 09:25 EDT http://www.prnewswire.com